Drugs / KHK2866
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01279291 | Jan 2011 → Nov 2012 | fallopian tube neoplasm, ovarian neoplasm, peritoneal neoplasm | Kyowa Kirin, Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KHK2866 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01279291 ↗ |
| Action | Inhibit | “All KHK2866 doses decreased serum free HB-EGF levels, generally below the lower limit of quantification.” PMID 26507836 ↗ Jun 2016 |
| Modality | Monoclonal antibody | “KHK2866 is a recombinant, humanized, non-fucosylated, monoclonal antibody directed at heparin-binding epidermal growth factor-like growth factor (HB-EGF).” PMID 26507836 ↗ Jun 2016 |
| Route | Intravenous | “MATERIALS AND METHODS: Using a standard 3 + 3 dose-escalation design, 20 patients received KHK2866 (0.3, 1, and 3 mg/kg) intravenously once weekly.” PMID 26507836 ↗ Jun 2016 |
| Target | HBEGF | “KHK2866 is a recombinant, humanized, non-fucosylated, monoclonal antibody directed at heparin-binding epidermal growth factor-like growth factor (HB-EGF).” PMID 26507836 ↗ Jun 2016 |